Search Patents
  • Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
    Patent number: 11655240
    Abstract: The present disclosure provides a crystal form of a compound and fumaric acid, an active pharmaceutical ingredient and a pharmaceutical composition containing the same, and a method for treating coronavirus-induced diseases a using the same. In particular, the crystal form of the present disclosure comprises the compound of Formula (I) and fumaric acid, and the X-ray powder diffraction pattern of the crystal form obtained using Cu-K? radiation includes at least three peaks selected from the group consisting of: 0.94°±0.2° 2?, 19.06°±0.2° 2?, 23.50°±0.2° 2?, and 24.66°±0.2° 2?. The crystal form of the present disclosure has a high purity, good stability, and a high melting point.
    Type: Grant
    Filed: October 12, 2022
    Date of Patent: May 23, 2023
    Assignees: BEIJING GRAND JOHAMU PHARMACEUTICAL COMPANY, LTD., NANJING GRITPHARMACO., LTD.
    Inventors: Weiye Wei, Jiannan Yang, Xiaotao Wu, Taotao Zhao, Hao Wang, Chao Li, Lei Qu, Bin Wang
  • DEVICES AND METHODS FOR DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
    Publication number: 20230082940
    Abstract: The invention discloses a biosensor device (100) to detect the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in a biological sample. The device includes an optical fiber probe (104) having a curved portion (104a) with a probe region (105) immobilized with bioreceptor molecules (201) configured to bind to the target molecule V indicative of the presence of the SARS-CoV-2. The probe has a light source (102) and a detector (106) on either end. The device works on the principle of plasmonic fiberoptic absorbance biosensing. Plasmonic gold nanoparticles (120) are used as either sensor substrate over the fiber or labels conjugated with a biorecognition molecule (211). The probe is exposed to a biological sample either directly for label-free detection, or after mixing with labels to realize a sandwich assay. The target biomolecules are detected by a proportional drop in the light intensity passing through the probe.
    Type: Application
    Filed: May 17, 2021
    Publication date: March 16, 2023
    Inventors: Raghavendra V.V. SAI, Himanshu BHATIA, Divagar MURUGAN
  • USE OF HEPARIN-BINDING PROTEIN (HBP) IN EARLY WARNING OF PROGNOSTIC RISK OF PATIENT SUFFERING CORONAVIRUS DISEASE (COVID-19)
    Publication number: 20230236195
    Abstract: Provided are a method for predicting a risk of deterioration of a pathogenic condition of a patient suffering a coronavirus disease (COVID-19), especially a severe patient suffering a COVID-19 and a kit thereof. The method of the present application may effectively predict the deterioration of the pathogenic condition of the patient suffering a COVID-19, thereby carrying out clinical intervention in advance, to improve prognosis of the patient suffering a COVID-19. The present application finds for the first time that the level of a heparin-binding protein (HBP) can be used as a significant indicator for early predicting relapse of the patient suffering a COVID-19, expression time of an HBP indicator is around 5 days earlier than that of a series of other clinical indicators, and thus the HBP indicator particularly has a clinical value.
    Type: Application
    Filed: January 23, 2023
    Publication date: July 27, 2023
    Applicant: JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD.
    Inventors: Baoqing SUN, Nanshan ZHONG, Xuyi ZHOU, Mingshan XUE, Longbin HONG, Ming DONG
  • NOVEL CORONAVIRUS NUCLEIC ACID RAPID HYBRID CAPTURE IMMUNOFLUORESCENCE DETECTION KIT, AND PREPARATION METHOD AND DETECTION METHOD THEREOF
    Publication number: 20230221304
    Abstract: The invention relates to the technical field of nucleic acid detection and discloses a novel coronavirus nucleic acid rapid hybrid capture immunofluorescence detection kit, and a preparation method and a detection method thereof. The kit includes a COVID-19 reaction solution, wherein the COVID-19 reaction solution is prepared from a COVID-19 fluorescence marker and a COVID-19 probe solution; and the COVID-19 probe solution includes: an ORFlab section probe, an N section probe and an E section probe. Compared with general fluorescence PCR and sequencing detection, the kit has the advantages of stronger signal intensity, better specificity, shorter detection time, no need of professional technicians for operation, no need of refrigeration in transportation and storage, no need of a matched laboratory and a matched PCR instrument, and convenience and rapidness in use.
    Type: Application
    Filed: February 24, 2021
    Publication date: July 13, 2023
    Inventors: Yang Lei, Jieli Zhang, Liwei Zhang, Renxun Huang, Jiawei Bai, Yicui Le, Xiao Hu, Daming Wang
  • Disinfectants with iodine and copper complexes for use against coronavirus
    Patent number: 11744249
    Abstract: Liquid antimicrobial disinfectant compositions for treatment of coronaviruses and specifically the Covid-19 virus (SARS-CoV-2) on skin and surfaces such as PPE (personal protective equipment) are disclosed that are highly efficacious and exhibit total eradication below detectable limits at 30 minutes (>6 log kill) against coronavirus (resulting in complete inactivation), while remaining non-toxic, safe and non-irritating (including at a cellular level and with extended contact) to skin and endogenous tissue.
    Type: Grant
    Filed: August 12, 2022
    Date of Patent: September 5, 2023
    Assignee: Clyra Medical Technologies, Inc.
    Inventors: Douglas J. Morgan, Steve Harrison, Tanya Rhodes
  • ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR
    Publication number: 20240016775
    Abstract: Provided is application of a poly ADP ribose polymerase inhibitor or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for the treatment of diseases caused by viruses, wherein the viruses are ?-coronavirus viruses. Also provided is application of a compound represented by formula III and/or a compound represented by formula IV or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for treatment of diseases caused by viruses, the viruses being HIV, HPV, EBV, IFV and/or coronaviruses.
    Type: Application
    Filed: February 24, 2021
    Publication date: January 18, 2024
    Applicant: FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD
    Inventors: Xiaokun SHEN, Liang XIAO, Zeng LI
  • Treatment of coronavirus infection
    Patent number: 7544712
    Abstract: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine,
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: June 9, 2009
    Assignee: National Health Research Insitutes
    Inventors: Tsu-An Hsu, Hsing-Pang Hsieh, Yu-Sheng Chao, Chi-Min Chen, Jia-Tsrong Jan, Hwan-Wun Liu
  • NOVEL CORONAVIRUS S PROTEIN DOUBLE-REGION SUBUNIT NANO-VACCINE BASED ON BACTERIAL COMPLEX
    Publication number: 20230090422
    Abstract: The present application is related to a novel coronavirus S protein double-region subunit nano-vaccine based on a bacterial complex. In the present invention, a receptor binding domain (RBD) and a fusion peptide (FP) of a virus are used together as double antigens, and are connected to a bacterial complex (such as PF_Ferritin or Lumazine Synthase (LS)) to form a fusion protein, so as to achieve antigen multimerization; and then expression is performed by using a eukaryotic cell expression system, and a 24-mer nano-antigen or a 60-mer nano-antigen can be formed by means of self-assembly action. The solution can overcome the defect of insufficient immunogenicity of an RBD monomer. The obtained vaccine can significantly increase the level of a neutralizing antibody against a virus in a host, and the resulting antibody has the capability of strongly blocking a virus from invading a target cell.
    Type: Application
    Filed: March 11, 2020
    Publication date: March 23, 2023
    Applicant: SUN YAT-SEN UNIVERSITY
    Inventors: Hui ZHANG, Xiancai MA, Fan ZOU, Yaochang YUAN, Rong LI, Xu ZHANG
  • Disinfectants with iodine and copper complexes for use against coronavirus
    Patent number: 11457632
    Abstract: Liquid antimicrobial disinfectant compositions for treatment of coronaviruses and specifically the Covid-19 virus (SARS-CoV-2) on skin and surfaces such as PPE (personal protective equipment) are disclosed that are highly efficacious and exhibit total eradication below detectable limits at 30 minutes (>6 log kill) against coronavirus (resulting in complete inactivation), while remaining non-toxic, safe and non-irritating (including at a cellular level and with extended contact) to skin and endogenous tissue.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: October 4, 2022
    Assignee: CLYRA Medical Technologies, Inc.
    Inventors: Douglas J. Morgan, Steve Harrison, Tanya Rhodes
  • CORONAVIRUS IgG/IgM MULTIPLEXED DUAL PATH IMMUNOASSAY DEVICE
    Publication number: 20210349083
    Abstract: Test cells with first and second sorbent materials defining a first flow path for a solution, a second flow path distinct from the first flow path for a sample, and a test site with immobilized antigens or antibodies or other ligand-binding molecules located at the junction of the sorbent materials for identifying one or more ligands. In one embodiment, a single highly sensitive immunoassay device is provided that detects the presence in a body fluid sample of two or more COVID-19 (Coronavirus disease 2019) antibodies including immunoglobulin M (IgM) and/or immunoglobulin G (IgG) antibodies to nucleocapsid protein (NP) and spike protein receptor binding domain (RBD), and optionally spike protein S1 subunit (S1) COVID-19 virus antigens. The immunoassay device is sensitive in detecting early infection using IgM antibody detection and continuing infection using IgG antibody detection. Additionally, successful inoculation is distinguished from infection after inoculation by comparing NP and RBD results.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 11, 2021
    Applicant: Chembio Diagnostic Systems, Inc.
    Inventor: Javanbakhsh Esfandiari
  • NEUTRALIZING MONO-SPECIFIC IgY ANTIBODIES TO INHIBIT OR TREAT SARS-COV-2 CORONAVIRUS INFECTION
    Publication number: 20230054807
    Abstract: Methods for producing mono-specific immunoglobin Y (IgY) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are disclosed. IgY antibodies are found in birds and can be isolated from egg yolk of chicken eggs. Hens are immunized with a SARS-CoV-2 spike protein comprising an ACE2 receptor binding domain (RBD). IgY antibodies against the RBD are isolated from eggs laid by the hens. The isolated RBD-IgY antibodies were tested in vitro in mammalian cells, wherein the RBD-IgY blocked SARS-CoV-2 infection of the cells. A pharmaceutical composition comprising the mono-specific IgY antibodies can be used to inhibit or treat COOVID-19, the SARS-CoV-2 infection. IgY antibodies are generally regarded as safe and offer various production and treatment advantages when compared to mammalian antibodies.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 23, 2023
    Inventors: Esam Ibraheem AZHAR, Sherif Ali EL-KAFRAWY, Aymn Talat ABBAS
  • COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION
    Publication number: 20230172912
    Abstract: The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof: wherein X and Y are independently selected from —CH2— and —O—, preferably are —CH2—; Z is N or C, preferably is N; m is an integer of from 0 to 3, preferably is 0; n is an integer of from 1 to 3, preferably is 1; R1 is, optionally substituted, C5-C6 cycloalkyl or aryl: R2 is, optionally substituted, aryl or heteroaryl; R3 and R4 are —H, or R3 and R4 together form a —CH2—CH2— bridge; R5 and R7 are independently selected from alkyl, preferably methyl and isopropyl; and in case Z is N, R6 is absent, or, in case Z is C, R6 together with R5 forms a —CH?CH—CH?CH— bridge; and/or (ii) a C—C chemokine receptor type 5 (CCR5) inhibitor, for use in treating and/or preventing pneumonia, sepsis, and/or coronavirus infection in a subject, and to methods, uses, kits an devices related thereto.
    Type: Application
    Filed: April 8, 2021
    Publication date: June 8, 2023
    Inventors: Torsten SCHALLER, Uta MERLE
  • Methods for producing recombinant coronavirus
    Publication number: 20040235132
    Abstract: A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon.
    Type: Application
    Filed: May 25, 2004
    Publication date: November 25, 2004
    Inventors: Kristopher M. Curtis, Boyd Yount, Ralph S. Baric
  • METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2
    Publication number: 20250130230
    Abstract: Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.
    Type: Application
    Filed: September 27, 2022
    Publication date: April 24, 2025
    Applicants: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, UNIVERSITY OF WASHINGTON
    Inventors: Chao Wang, Liangcai Gu, Xiahui Chen, Shoukai Kang, MD Ashif Ikbal, Zhi Zhao
  • PROTEIN-DERIVED PEPTIDE FOR IMPROVING IMMUNITY AGAINST 2019 NOVEL CORONAVIRUS (2019-nCoV) AND USE THEREOF
    Publication number: 20240279279
    Abstract: In some embodiments, the disclosure provides a hazelnut-derived peptide with an inhibitory activity against a 2019 novel coronavirus main protease (2019-nCoV M-pro), including an amino acid sequence of Trp-Trp-Asn-Leu-Asn (WWNLN). In other embodiments, the disclosure provides use of the hazelnut-derived peptide with an inhibitory activity against a 2019-nCoV M-pro in preparation of a drug, a health product, or a food supplementary for inhibiting a 2019-nCoV infection. In further embodiments, the derived peptide WWNLN in the disclosure has a high 2019-nCoV M-pro inhibitory activity, with an inhibition rate of 74.13%±1.93% and a half maximal inhibitory concentration (IC50) value of 6.695 ?M. In some embodiments, the derived peptide may be used to prepare drugs, health products, or foods supplementary that inhibit 2019-nCoV infections, and may show desirable application prospects.
    Type: Application
    Filed: February 21, 2024
    Publication date: August 22, 2024
    Applicant: ZHEJIANG A&F UNIVERSITY
    Inventors: Weihong MIN, Fanrui ZHAO
  • Coronavirus isolated from humans
    Patent number: 7220852
    Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: May 22, 2007
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Suxiang Tong, Sherif R. Zaki
  • Coronavirus IgG/IgM multiplexed dual path immunoassay device
    Patent number: 12111312
    Abstract: Test cells with first and second sorbent materials defining a first flow path for a solution, a second flow path distinct from the first flow path for a sample, and a test site with immobilized antigens or antibodies or other ligand-binding molecules located at the junction of the sorbent materials for identifying one or more ligands. In one embodiment, a single highly sensitive immunoassay device is provided that detects the presence in a body fluid sample of two or more COVID-19 (Coronavirus disease 2019) antibodies including immunoglobulin M (IgM) and/or immunoglobulin G (IgG) antibodies to nucleocapsid protein (NP) and spike protein receptor binding domain (RBD), and optionally spike protein S1 subunit (S1) COVID-19 virus antigens. The immunoassay device is sensitive in detecting early infection using IgM antibody detection and continuing infection using IgG antibody detection. Additionally, successful inoculation is distinguished from infection after inoculation by comparing NP and RBD results.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: October 8, 2024
    Assignee: Chembio Diagnostic Systems, Inc.
    Inventor: Javanbakhsh Esfandiari
  • 3-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20230391736
    Abstract: The present invention relates to the technical field of medicinal chemistry, and particularly to a method for preparing a 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione compound inhibiting coronavirus 3CL protease activity and use thereof. Specifically, a compound of Formula I, or a pharmaceutically acceptable salt, or an optical isomer, or an isotope-substituted form thereof is provided. The compound effectively inhibits the SARS-CoV-2 3CLpro activity, and is useful in the preparation of a SARS-CoV-2 3CLpro inhibitor to block the replication and transcription of SARS-CoV-2 viruses in patients. The compound prepared in the present invention has high in-vitro safety, and very good prospect of application in the preparation of SARS-CoV-2 3CLpro inhibitors and anti-SARS-CoV-2 drugs.
    Type: Application
    Filed: March 18, 2023
    Publication date: December 7, 2023
    Inventors: Xiaolin XIE, Dezhu Zhang, Zhao Ma, Boyang Li, Xuhua Zhou, Chengyuan Liang, Liang Xin, Lei Tian, Jingyi Li, Kangxiong Wu, Shaojun Zhang, Xiuding Yang, Sundian Liu, Yuting Liu
  • BLOCKING ELISA KIT FOR DETECTING ANTIBODY TO SWINE ACUTE DIARRHEA SYNDROME CORONAVIRUS N PROTEIN
    Publication number: 20230194526
    Abstract: The disclosure belongs to the field of biotechnology, and in particular to a blocking ELISA kit for detecting an antibody to swine acute diarrhea syndrome coronavirus (SADS-CoV) N protein. The kit includes an enzyme plate coated with SADS-CoV N protein, an HRP-labeled mouse anti-SADS-CoV N protein monoclonal antibody (mAb), a positive serum control, and a negative serum control. The kit may detect positive sera diluted at 1:512, with no cross-reaction with positive sera against porcine epidemic diarrhea virus (PEDV), transmissible gasteroenteritis virus (TGEV) and porcine deltacoronavinis (PDCoV) etc., and the intrabatch and interbatch coefficient of variation is less than 10%. The comparison result with the indirect immunofluorescence test shows that the concordance rate of the blocking ELISA kit of the present disclosure is 99.6%, the Kappa value is 0.91, and the blocking ELISA method established by the present disclosure is highly consistent with IFA.
    Type: Application
    Filed: July 8, 2022
    Publication date: June 22, 2023
    Inventors: QI WANG, LIYAN CAO, HAIXUE ZHENG, HONG TIAN, XIANGYU KONG, CONG YUAN, YUEYUE DUAN
  • METHODS FOR DETECTING THE PRESENCE OF CORONAVIRUS-SPECIFIC ANTIBODIES IN A SUBJECT
    Publication number: 20230194528
    Abstract: Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26-32 kilobases in length. In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, reliable diagnostic methods are highly desirable. In particular, the development and availability of tests for the detection and quantification of anti-SARS-CoV-2 antibodies in subjects with COVID-19 is of strong diagnostic interest. The present fulfils this need. In particular, the inventors developed an 15 Adressable Laser Beads ImmunoAssay (ALBIA) method based on the use of particles conjugated with a coronaviral polypeptides (S1,S2, S2?, N, PL-Pro).
    Type: Application
    Filed: April 13, 2021
    Publication date: June 22, 2023
    Inventors: Olivier BOYER, Laurent DROUOT
Narrow Results

Filter by US Classification